166 related articles for article (PubMed ID: 31637877)
1. Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages.
Behring M; Vazquez AI; Cui X; Irvin MR; Ojesina AI; Agarwal S; Manne U; Shrestha S
Mol Genet Genomic Med; 2019 Dec; 7(12):e1001. PubMed ID: 31637877
[TBL] [Abstract][Full Text] [Related]
2. Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
Pollock NC; Ramroop JR; Hampel H; Troester MA; Conway K; Hu JJ; Freudenheim JL; Olopade OI; Huo D; Ziv E; Neuhausen SL; Stevens P; McElroy JP; Toland AE
Breast Cancer Res Treat; 2022 Apr; 192(3):639-648. PubMed ID: 35286522
[TBL] [Abstract][Full Text] [Related]
3. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Kim JY; Jung J; Kim KM; Lee J; Im YH
Cancer Med; 2023 Jun; 12(11):12438-12451. PubMed ID: 37081749
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
[TBL] [Abstract][Full Text] [Related]
7. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
9. Association of
Tjader NP; Beer AJ; Ramroop J; Tai MC; Ping J; Gandhi T; Dauch C; Neuhausen SL; Ziv E; Sotelo N; Ghanekar S; Meadows O; Paredes M; Gillespie J; Aeilts A; Hampel H; Zheng W; Jia G; Hu Q; Wei L; Liu S; Ambrosone CB; Palmer JR; Carpten JD; Yao S; Stevens P; Ho WK; Pan JW; Fadda P; Huo D; Teo SH; McElroy JP; Toland AE
medRxiv; 2023 Dec; ():. PubMed ID: 38106140
[TBL] [Abstract][Full Text] [Related]
10. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
11. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
12. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.
Quigley D; Silwal-Pandit L; Dannenfelser R; Langerød A; Vollan HK; Vaske C; Siegel JU; Troyanskaya O; Chin SF; Caldas C; Balmain A; Børresen-Dale AL; Kristensen V
Mol Cancer Res; 2015 Mar; 13(3):493-501. PubMed ID: 25351767
[TBL] [Abstract][Full Text] [Related]
13. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
[TBL] [Abstract][Full Text] [Related]
14. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.
Kuo SJ; Chen M; Ma GC; Chen ST; Chang SP; Lin WY; Chen YC; Lee TH; Lin TT; Liu CS
Cancer Genet Cytogenet; 2010 Sep; 201(2):94-101. PubMed ID: 20682393
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations in breast cancer tumors of patients from Rio de Janeiro, Brazil: association with risk factors and tumor characteristics.
Simão TA; Ribeiro FS; Amorim LM; Albano RM; Andrada-Serpa MJ; Cardoso LE; Mendonça GA; de Moura-Gallo CV
Int J Cancer; 2002 Sep; 101(1):69-73. PubMed ID: 12209590
[TBL] [Abstract][Full Text] [Related]
16. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
17. Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer.
Hao XD; Yang Y; Song X; Zhao XK; Wang LD; He JD; Kong QP; Tang NL; Zhang YP
Oncol Rep; 2013 Jan; 29(1):226-36. PubMed ID: 23124483
[TBL] [Abstract][Full Text] [Related]
18. SnapShot: TP53 status and macrophages infiltration in TCGA-analyzed tumors.
El-Arabey AA; Abdalla M; Abd-Allah AR
Int Immunopharmacol; 2020 Sep; 86():106758. PubMed ID: 32663767
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma.
O'Sullivan DE; Johnson KC; Skinner L; Koestler DC; Christensen BC
Epigenetics; 2016 May; 11(5):344-53. PubMed ID: 27070496
[TBL] [Abstract][Full Text] [Related]
20. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
